VOR Vor Biopharma

Vor Bio to Participate in Upcoming Investor Conferences

Vor Bio to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that it will participate in the following upcoming investor conferences:

Citi's 2025 Biopharma Back to School Conference

Fireside Chat: Tuesday, September 2nd, 2025, at 11:15am ET

Location: Boston, MA

A live webcast and archived replay of the fireside chat will be available on the investors section of .

Baird 2025 Global Healthcare Conference

1x1 Investor Meetings: Tuesday, September 9th, 2025

Location: New York, NY

About Vor Bio

Vor Bio is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The Company is focused on rapidly advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development and commercialization to address serious autoantibody-driven conditions worldwide. For more information visit .

Media & Investor Contacts:

Carl Mauch

Sarah Spencer



EN
26/08/2025

Underlying

VORVor Biopharma

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Vor Biopharma

 PRESS RELEASE
Free
VOR VOR BIOPHARMA

Vor Bio to Participate in Upcoming Investor Conferences

Vor Bio to Participate in Upcoming Investor Conferences CAMBRIDGE, Mass., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that it will participate in the following upcoming investor conferences: Citi's 2025 Biopharma Back to School ConferenceFireside Chat: Tuesday, September 2nd, 2025, at 11:15am ETLocation: Boston, MA A live webcast and archived replay of the fireside chat will be available on the investors section of . Baird 2025 Global Healthcare Conference 1x1 Investor...

9h / 20m 1 EN
 PRESS RELEASE
Free
VOR VOR BIOPHARMA

Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CAMBRIDGE, Mass., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, between August 4, 2025, and August 18, 2025, the Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 6,959,013 shares of Vor Bio’s common stock and restricted stock units (“RSUs”) representing the right to receive an aggregate of 1,491,217 shares of Vor Bio’s common stock to seven newly hi...

August 18, 2025 1 EN
 PRESS RELEASE
Free
VOR VOR BIOPHARMA

Telitacicept Achieved Primary Endpoint in Phase 3 Clinical Study for P...

Telitacicept Achieved Primary Endpoint in Phase 3 Clinical Study for Primary Sjögren's Disease with Telitacicept, a Dual BAFF/APRIL Inhibitor Phase 3 results position telitacicept as potential best-in-disease profile in primary Sjögren's disease Telitacicept demonstrated a favorable safety profile Vor evaluating timing of global Phase 3 clinical study in primary Sjögren's disease Data anticipated to be presented at an upcoming medical conference CAMBRIDGE, Mass., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment ...

August 13, 2025 1 EN
Wedbush Research
  • Wedbush Research
PHM PULTEGROUP INC.
FATE FATE THERAPEUTICS INC
BIIB BIOGEN INC.
SE SEA ADS
STOK STOKE THERAPEUTICS
PASG PASSAGE BIO
ORIC ORIC PHARMACEUTICALS
GBIO GENERATION BIO
VOR VOR BIOPHARMA
PHVS PHARVARIS NV
ATXS ASTRIA THERAPEUTICS INC
ARTV ARTIVA BIOTHERAPEUTICS INC
SLDB SOLID BIOSCIENCES INC
DDI DOUBLEDOWN INTERACTIVE CO LTD
RNAC CARTESIAN THERAPEUTICS INC
MAZE MAZE THERAPEUTICS INC
08/13/25 August 13, 2025 1 EN
David Nierengarten ... (+3)
  • David Nierengarten
  • Dennis Pak
  • Martin Fan
08/13/25 August 13, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch